aid: aviceda-therapeutics
name: Aviceda Therapeutics
description: 'Aviceda Therapeutics is a private, late-stage clinical biotechnology company
  based in Cambridge, Massachusetts that describes itself as the world leader in glyco-immune
  checkpoint therapeutics. It develops immune-mediated therapies built on a glyco-mimetic
  nanoparticle platform that targets the interaction between sialic acids on cell surfaces
  and Siglec immune receptors in order to modulate aberrant inflammation. Its lead asset,
  AVD-104, is an intravitreally administered sialic-acid-coated nanoparticle being evaluated
  in the Phase 2/3 SIGLEC trial for geographic atrophy secondary to age-related macular
  degeneration. Aviceda is a therapeutics developer, not a software vendor: it publishes
  no developer program, no public API, and no machine-readable API artifacts.'
url: https://raw.githubusercontent.com/api-evangelist/aviceda-therapeutics/refs/heads/main/apis.yml
image: https://www.avicedarx.com/media/logo/aviceda.svg
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.23'
created: '2026-08-06'
modified: '2026-08-06'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Therapeutics
- Ophthalmology
- Clinical Trials
- Life Sciences
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/aviceda-therapeutics-domain-security.yml
- type: Website
  url: https://www.avicedarx.com/
- type: About
  url: https://www.avicedarx.com/about-us
- type: Contact
  url: https://www.avicedarx.com/contact
- type: Careers
  url: https://www.avicedarx.com/careers
- type: News
  url: https://www.avicedarx.com/company-updates
- type: Investors
  url: https://www.avicedarx.com/investors
- type: LinkedIn
  url: https://www.linkedin.com/company/aviceda-therapeutics/
- type: Twitter
  url: https://twitter.com/avicedarx
- type: SecondaryMarket
  url: https://forgeglobal.com/aviceda-therapeutics_stock/
x-enrichment:
  date: '2026-08-06'
  status: minimal
  artifacts_added: 1
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Aviceda is a clinical-stage biotech developing the AVD-104 nanoparticle for
    geographic atrophy; its entire web presence is a ten-page corporate brochure at
    avicedarx.com (sitemap.xml lists only home, technology-platform, lead-asset, pipeline,
    publications, company-updates, about-us, investors, careers, contact) with no developer
    section, and api./developer./docs.avicedarx.com do not resolve in DNS.
  evidence:
  - url: https://www.avicedarx.com/sitemap.xml
    status: 200
  - url: https://www.avicedarx.com/openapi.json
    status: 404
  - url: https://www.avicedarx.com/.well-known/agent-card.json
    status: 404
  checked: '2026-08-06'